Development and Commercialization of Licensed Products Sample Clauses
The "Development and Commercialization of Licensed Products" clause defines the obligations and rights of the parties regarding the creation, improvement, and marketing of products covered by the license agreement. Typically, this clause outlines the licensee's responsibility to use reasonable efforts to develop the licensed products, meet certain milestones, and bring them to market, sometimes specifying timelines or performance benchmarks. Its core practical function is to ensure that the licensed technology or intellectual property is actively developed and commercialized, thereby maximizing its value and benefiting both parties.
POPULAR SAMPLE Copied 1 times
Development and Commercialization of Licensed Products. As between the Parties, K▇▇▇▇▇ shall have sole control, authority, and discretion over the research, development, manufacture and commercialization of Licensed Products throughout the world, subject to Section 3.3. If K▇▇▇▇▇ ▇▇▇▇▇ any Licensed Product as part of a bundle, or as part of a combination therapy where K▇▇▇▇▇ has the right to sell and set the price of the other component of the combination therapy, then Kineta shall not disproportionately discount, in a manner inconsistent with the relative value of the components of such combination therapy or bundle, the pricing of the Licensed Product relative to the other components. K▇▇▇▇▇ shall not use any Licensed Product as a loss leader.
Development and Commercialization of Licensed Products. Except with respect to the activities being conducted by the Parties under the Research Programs and Optimization Programs, as between Licensee and Arvinas, following the first exercise of an Option for an Exclusive Target pursuant to Section 3.2 above, (i) Licensee shall have sole responsibility for, and bear all costs for, researching, developing and commercializing Licensed Products in the Field in the Territory; and (ii) subject to the obligations expressly set forth herein, Licensee shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products in the Field in the Territory.
Development and Commercialization of Licensed Products. Immune Design shall have the sole responsibility and the sole discretion to research, develop and commercialize Licensed GLA Product(s) in the Immune Design Exclusive Field and in the *** Field in that part of the Territory that is outside the IDRI Territory.
Development and Commercialization of Licensed Products. As between the Parties, Poseida shall have sole control, authority, and discretion over the research, development, manufacture and commercialization of Licensed Products in the Field in the Territory, subject to Section 3.3.
Development and Commercialization of Licensed Products. Except with respect to the activities being conducted by the Parties under the Research Programs, as between GNE and Immunocore (i) GNE shall have sole responsibility for and bear all costs for, researching, developing and commercializing Licensed Products; and (ii) GNE shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products. On an Exclusive Target-by-Exclusive Target basis, GNE agrees to use Diligent Efforts to research, develop and commercialize at least one Licensed Product that binds to an HLA-presented antigen derived from each Exclusive Target within the Field in the Territory.
Development and Commercialization of Licensed Products. As between Licensee and Kineta,
5.1.1 Prior to Licensee’s exercise of the Option, Kineta shall (i) have sole responsibility for, bear all costs for, developing and commercializing Licensed Products; (ii) have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products (excepting Licensee activities as outlined in the Research and Early Development Plan); (iii) perform its Research and Early Development Plan activities and provide the results of same to Licensee using Diligent Efforts; and (iv) deliver any other documents (including regulatory filings) that Licensee reasonably requests to exercise the Option and Kineta-Genentech Exclusive Option and License Agreement
5.1.2 Following Licensee’s exercise of the Option, (i) Licensee shall have sole responsibility for, bear all costs for, researching, developing and commercializing Licensed Products; and (ii) Licensee shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products. Following Licensee’s exercise of the Option, Licensee agrees to use Diligent Efforts to research, develop and commercialize at least one Licensed Product within the Field in the Territory.
5.1.3 Following Licensee’s exercise of the Option, K▇▇▇▇▇ shall use Diligent Efforts to complete the Technology Transfer as applicable.
Development and Commercialization of Licensed Products. The Company undertakes to develop Licensed Products in the Field, for application in the following end-user categories:
Development and Commercialization of Licensed Products. The Company undertakes to develop Licensed Products in the Field, for application in the following end-user categories: Over-The-Counter Products Prescription Medical Food Products Prescription Drug Products. The Company shall be responsible, at its own cost, for the development, for the conduct of all clinical research required as well as for the commercialization of the Licensed Products in the Licensed Field. The Company agrees that the Licensed Products to be commercialized shall always conform to the following specifications: o The concentration of phospholipids contained in the Licensed Products shall be [REDACTED: Concentration]. The Company must ensure that the above-concentrations of phospholipids are stable within the Licensed Products [REDACTED: Period]. Please refer to: the action taken by ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ against Université de Sherbrooke, Groupe Conseil ▇▇▇▇▇▇▇ and Neptune Technologies & Bioressources Inc. in the Province of Quebec, district of Laval, file number 540-17-001287-043; and the following opposition: Opposition details: European Patent No. 1 417 211 Title: Natural phospholipids of marine origin containing flavonoids and polyunsaturated fatty acids and their uses Status: Granted 30 May 2007 on application no. 02753988.1 Proprietor: Neptune Technologies and Bioressources Inc. Opposing parties:
Development and Commercialization of Licensed Products. Except with respect to the activities being conducted by the Parties under the Research Programs and subject to AFMD’s co-promotion option pursuant to Section 7.3 below, as between NewCo and AFMD, NewCo shall have sole responsibility for, bear all costs for, researching, developing and commercializing Licensed Products, including all regulatory matters in relation thereto. NewCo shall own all related regulatory filings or approvals, including IND filings and Marketing Approvals with respect to the Licensed Products. On an Exclusive Target-by-Exclusive Target basis, NewCo agrees to use Diligent Efforts to research, develop and commercialize in one of the US, EU or Japan at least one Licensed Product that binds to each Exclusive Target.
Development and Commercialization of Licensed Products. As between the Parties, Licensee (itself and with its Affiliates and Sublicensees) shall have sole right and responsibility, and ultimate decision-making authority, at its sole cost and expense, for conducting or having conducted development activities, regulatory activities (including, without limitation, filing for and obtaining Regulatory Approval, as applicable), manufacturing activities and commercialization activities in the Field of Use in the Licensed Territories with respect to any Licensed Products, in accordance with the terms and conditions of this Agreement. As between the Parties, Licensee (or its Affiliate or Sublicensee) shall hold legal title to all Regulatory Materials with respect to Licensed Products within the Licensed Territories.